Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
Nov 2024
Historique:
medline: 2 11 2024
pubmed: 2 11 2024
entrez: 1 11 2024
Statut: ppublish

Résumé

Kirsten rat sarcoma virus (KRAS)-G12C inhibition causes remodeling of the lung tumor immune microenvironment and synergistic responses to anti-PD-1 treatment, but only in T cell infiltrated tumors. To investigate mechanisms that restrain combination immunotherapy sensitivity in immune-excluded tumors, we used imaging mass cytometry to explore cellular distribution in an immune-evasive KRAS mutant lung cancer model. Cellular spatial pattern characterization revealed a community where CD4

Identifiants

pubmed: 39485838
doi: 10.1126/sciadv.adl6464
doi:

Substances chimiques

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2
Programmed Cell Death 1 Receptor 0
KRAS protein, human 0
Hras protein, mouse EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadl6464

Auteurs

Megan Cole (M)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Panayiotis Anastasiou (P)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Claudia Lee (C)

Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.

Xiaofei Yu (X)

Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.

Andrea de Castro (A)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Jannes Roelink (J)

Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Chris Moore (C)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Edurne Mugarza (E)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Martin Jones (M)

Electron Microscopy, Francis Crick Institute, London, UK.

Karishma Valand (K)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Sareena Rana (S)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Emma Colliver (E)

Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.

Mihaela Angelova (M)

Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.

Katey S S Enfield (KSS)

Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.

Alastair Magness (A)

Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.

Asher Mullokandov (A)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Gavin Kelly (G)

Bioinformatics and Biostatistics, Francis Crick Institute, London, UK.

Tanja D de Gruijl (TD)

Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.
Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.

Miriam Molina-Arcas (M)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Charles Swanton (C)

Cancer Evolution and Genome Instability Laboratory, Francis Crick Institute, London, UK.
Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK.

Julian Downward (J)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.

Febe van Maldegem (F)

Oncogene Biology Laboratory, Francis Crick Institute, London, UK.
Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.
Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH